Optimizing Induction Chemoimmunotherapy and Supportive Care in ES-SCLC

This segment focuses on first-line induction therapy for extensive-stage small cell lung cancer. Panelists explain why carboplatin plus etoposide remains the preferred chemotherapy backbone for most patients alongside a PD-L1 inhibitor. They reserve cisplatin for select younger, very fit individuals with strong renal function. They discuss the standard number of induction cycles, the rare circumstances in which they might extend therapy, and the practical realities of dose delays driven by neutropenia, nausea, and fatigue. Supportive care strategies are reviewed, including growth factor support and trilaciclib for myelopreservation, with attention to how institutional formularies shape access and how anemia can compound treatment-related fatigue. The faculty then examine consolidative thoracic radiation and explain why recent data have moved it away from routine use, noting an ongoing trial designed to clarify its role. The segment closes by exploring why maintenance therapy matters in a disease marked by high initial response rates followed by rapid relapse.